Xencor Inc
Change company Symbol lookup
Select an option...
XNCR Xencor Inc
ALT Altimmune Inc
RZLT Rezolute Inc
BNKU MicroSectors? U.S. Big Banks Index 3X Leveraged ETNs
SGFY Signify Health Inc
FRC First Republic Bank
BACK IMAC Holdings Inc
LYLT Loyalty Ventures Inc
BOXD Boxed Inc
ALLR Allarity Therapeutics Inc

Health Care : Biotechnology | Small Cap Blend
Company profile

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company is advancing a portfolio of clinical-stage XmAb drug candidates from its protein engineering technology platforms. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design technologies and XmAb development candidates with properties. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Tidutamab, XmAb841, XmAb306, AMG 509, XmAb819, XmAb104, XmAb564 and Novartis XmAb.

Day's Change
-0.185 (-0.64%)
B/A Size
Day's High
Day's Low

Today's volume of 27,503 shares is on pace to be much lighter than XNCR's 10-day average volume of 505,883 shares.


Societe Generale, AllianceBernstein form equities joint venture

4:02 am ET November 22, 2022 (MarketWatch)

By Ed Frankl

Societe Generale SA said Tuesday that it agreed to combine its cash-equities and equity-research businesses with that of U.S. asset manager AllianceBernstein Holding LP.

The French bank said the joint venture with Bernstein Research Services would provide investment advice into the U.S., European and Asia-Pacific equity markets, alongside liquidity access and global-trading technology.

Societe Generale expects to take a 51% interest in the joint venture, with an option to reach 100% ownership after five years, with closure expected by the end of 2023, it said.

The business would be run as a long-term partnership under the Bernstein name, based in London, with Bernstein Research Services' Chief Executive Robert van Brugge as head, Societe Generale said.

The deal would boost profitability, on a return-on-tangible-equity basis, of between 15 and 20 basis point from 2025, the Paris-based lender added.

"The merged entities would bring complementary strengths and a shared vision of a leading full-service equity brokerage business to support the needs of global investor and issuer clients," the bank said.

Write to Ed Frankl at edward.frankl@dowjones.com

-Ed Frankl


(END) Dow Jones Newswires

November 22, 2022 04:02 ET (09:02 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.